Evaluating only CellenkOS’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market collapse.
Key Events Timeline
FOUNDING
CellenkOS founded in Houston using cord blood-derived Treg cells to treat GVHD and inflammatory diseases.
FUNDING
$20M Series A raised from Texas-based healthcare investors; CK0801 Treg therapy enters Phase 1 for GVHD.
DOWN ROUND
Planned $50M Series B fails to close; biotech funding market collapse makes Treg cell therapy unattractive to VCs.
SHUTDOWN
CellenkOS shuts down; all employees terminated, 28 total patients treated across all clinical programs.
Full Analysis
Free · no account needed
Documented cause
CellenkOS, a Houston-based T-regulatory cell therapy company targeting graft-versus-host disease and ALS, ran out of funding in Q3 2023 after raising only $35M total — insufficient to complete even a single Phase 2 trial. Founder and CEO Simrit Parmar failed to close a planned $50M Series B in early 2023 as biotech market conditions collapsed. The company had treated only 28 patients across all programs. All staff were let go in August 2023 with no acquirer or licensing deal secured.
Lesson
“Cell therapy companies need $100M+ minimum before IND; $35M total is insufficient for any clinical validation.”